Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy

被引：29

作者：

van Praag, RME

van Weert, ECM

van Heeswijk, RPG

Zhou, XJ

Sommadossi, JP

Jurriaans, S

Lange, JMA

Hoetelmans, RMW

Prins, JM

机构：

[1] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NATEC,Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands

[2] Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands

[3] Slotervaart Hosp, Dept Pharm & Pharmacol, Amsterdam, Netherlands

[4] Univ Alabama, Dept Pharmacol & Toxicol, Birmingham, AL USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2002年 / 46卷 / 03期

关键词：

D O I：

10.1128/AAC.46.3.896-899.2002

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

For a number of antiretroviral drugs, prolonged suppression of viral replication is related to drug exposure. Therefore, it is important to maintain stable concentrations during prolonged therapy. While studies suggest that saquinavir concentrations decrease over time, we show that concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid are stable during 2 years of therapy.

引用

页码：896 / 899

页数：4

共 20 条

[1] Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase [J].

Antonelli, G ;

Turriziani, O ;

Verri, A ;

Narciso, P ;

Ferri, F ;

DOffizi, G ;

Dianzani, F .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (03) :223-228

[2] The role of therapeutic drug monitoring in treatment of HIV infection [J].

Back, DJ ;

Khoo, SH ;

Gibbons, SE ;

Merry, C .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (04) :301-308

[3]

Gibaldi M, 1991, BIOPHARMACEUTICS CLI, P14

[4] Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir [J].

Gisolf, EH ;

van Heeswijk, RPG ;

Hoetelmans, RWM ;

Danner, SA .

AIDS, 2000, 14 (07) :801-805

[5] 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine [J].

Gulick, RM ;

Mellors, JW ;

Havlir, D ;

Eron, JJ ;

Meibohm, A ;

Condra, JH ;

Valentine, FT ;

McMahon, D ;

Gonzalez, C ;

Jonas, L ;

Emini, EA ;

Chodakewitz, JA ;

Isaacs, R ;

Richman, DD .

ANNALS OF INTERNAL MEDICINE, 2000, 133 (01) :35-39

[6] HIGH-DOSE NEVIRAPINE - SAFETY, PHARMACOKINETICS, AND ANTIVIRAL EFFECT IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].

HAVLIR, D ;

CHEESEMAN, SH ;

MCLAUGHLIN, M ;

MURPHY, R ;

ERICE, A ;

SPECTOR, SA ;

GREENOUGH, TC ;

SULLIVAN, JL ;

HALL, D ;

MYERS, M ;

LAMSON, M ;

RICHMAN, DD .

JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (03) :537-545

[7] Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir [J].

Kakuda, TN ;

Page, LM ;

Anderson, PL ;

Henry, K ;

Schacker, TW ;

Rhame, FS ;

Acosta, EP ;

Brundage, RC ;

Fletcher, CV .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :236-242

[8]

Khaliq Y, 1998, AIDS, V12, pS28

[9] Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients [J].

Marzolini, C ;

Telenti, A ;

Decosterd, LA ;

Greub, G ;

Biollaz, J ;

Buclin, T .

AIDS, 2001, 15 (01) :71-75

[10] The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1 [J].

Moore, KHP ;

Barrett, JE ;

Shaw, S ;

Pakes, GE ;

Churchus, R ;

Kapoor, A ;

Lloyd, J ;

Barry, MG ;

Back, D .

AIDS, 1999, 13 (16) :2239-2250

← 1 2 →